Nicotinamide-Adenine Dinucleotide (NADH) in Parkinson's Disease and Alzheimer's Disease

Author(s):  Glasnapp Andrew, Schaefer Erin

Issue:  Jul/Aug 2000 - Compounding for Hospice and Cancer Patients
View All Articles in Issue

Abstract:  Nicotinamide-adenine dinucleotide (NADH) is currently being tested as a promising new therapy in the treatment of Parkinson’s and Alzheimer’s disease. The authors discuss some of these studies, in addition to providing figures showing the synthesis of dopamine and the Kreb’s cycle and providing tables showing results of the Birkmayer Parkinison’s Disease Study and the Mini-Mental State Examination. They also provide a formulation for NADH Capsules.

Related Keywords: adenine, alzheimer's, coenzyme I, dinucleotide, dopamine, levodopa, mini-mental state exam, motor function, NADH, neurochemistry, neurology, Nicotinamide, parkinson's, tetrahydrobiopterin, tyrosine

Related Categories: GERIATRICS, MENTAL HEALTH

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=494

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products